Vueway Generic Name & Formulations
Single-dose vials (3mL, 7.5mL, 10mL, 15mL)—1, 10; Single-dose prefilled syringes (7.5mL, 10mL, 15mL)—1, 10
For use in MRI of the CNS (brain, spine, and associated tissues) and the body (head, neck, thorax, abdomen, pelvis, and musculoskeletal system) in adults and children to detect and visualize lesions with abnormal vascularity.
Vueway Dosage and Administration
Adults and Children
<2yrs: not established. Give by IV bolus inj at a rate of ~2mL/sec manually or by compatible power injector. ≥2yrs: 0.05mmol/kg (0.1mL/kg), followed by a normal saline IV flush.
Vueway Boxed Warnings
Nephrogenic systemic fibrosis.
Increased risk for nephrogenic systemic fibrosis in chronic kidney disease or acute kidney injury; avoid use. Screen for renal dysfunction. Do not exceed recommended dose and allow sufficient time for drug elimination before re-administration. Have emergency resuscitative equipment available. History of asthma or other allergic disorders. Monitor for signs/symptoms of hypersensitivity reactions during and after administration. Increased risk of gadolinium retention with multiple lifetime doses, in pregnant patients, children, and those with inflammatory conditions; minimize repetitive imaging studies. Avoid extravasation. Interpreting Vueway MRI scans without a companion non-contrast MRI. Renal impairment. Elderly. Pregnancy. Nursing mothers.
The mean (CV%) volume of distribution at steady state is 13 (13%) L.
Plasma protein bound ≤1.8%.
Renal (~98%). Half-life: 1.5 hours.
Vueway Adverse Reactions
Inj site pain, headache, nausea, inj site warmth and coldness, dizziness, localized swelling.
Vueway Clinical Trials
Vueway Patient Counseling